Company intelligence / Profile preview

Zymenex

Ownership: Private
Development stage: Phase 3

Overview

Zymenex was a Scandinavian biopharmaceutical company specializing in the development and commercialization of novel enzyme replacement therapies for severe, inherited lysosomal storage diseases. Its lead program, Lamazym® (velmanase alfa), targeted alpha-mannosidosis and reached Phase III clinical trials before being acquired by Chiesi Farmaceutici. The drug has since been approved as Lamzede® in Europe. Other pipeline assets included Metazym for MLD and Galaczym for Krabbe’s disease. The company was known for its focus on orphan drugs addressing unmet needs in rare genetic disorders.[4][6]

Therapeutic areas: Rare DiseasesNeurologyMetabolic Disorders
Modalities: Enzyme replacement therapies (recombinant human enzymes)[1][4]
Industry: Biotech

Drug pipeline

3 assets

Lamazym

Phase 3

Indications: Alpha-mannosidosis

2 more assets in the full pipeline.

Request access →

Partnerships

EU Framework Programme grants supported clinical trials.Shire Pharmaceuticals acquired rights to Metazym.[6]

Beyond the preview

Go deeper on Zymenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zymenex.

Explore the full profile